BR9914899A - Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo - Google Patents

Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo

Info

Publication number
BR9914899A
BR9914899A BR9914899-4A BR9914899A BR9914899A BR 9914899 A BR9914899 A BR 9914899A BR 9914899 A BR9914899 A BR 9914899A BR 9914899 A BR9914899 A BR 9914899A
Authority
BR
Brazil
Prior art keywords
tofisopam
prevention
treatment
composition
anxiety disorders
Prior art date
Application number
BR9914899-4A
Other languages
English (en)
Inventor
Donald W Landry
Donald F Klein
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of BR9914899A publication Critical patent/BR9914899A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>''USO DE (R)-TOFISOPAM OPTICAMENTE PURO PARA O TRATAMENTO E A PREVENçãO DE DISTúRBIOS DE ANSIEDADE E COMPOSIçãO DO MESMO''<D>. São divulgados métodos que utilizam o enantiómero R de tofisopam. Este composto é útil no tratamento ou na prevenção de ansiedade ou distúrbios de ansiedade, ao mesmo tempo reduzindo substancialmente os efeitos adversos associados com o tofisopam racêmico.
BR9914899-4A 1998-10-27 1999-10-27 Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo BR9914899A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Publications (1)

Publication Number Publication Date
BR9914899A true BR9914899A (pt) 2001-07-17

Family

ID=22307874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914899-4A BR9914899A (pt) 1998-10-27 1999-10-27 Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo

Country Status (16)

Country Link
EP (1) EP1124556B1 (pt)
JP (2) JP2003522112A (pt)
AT (1) ATE269705T1 (pt)
AU (1) AU1451900A (pt)
BR (1) BR9914899A (pt)
CA (1) CA2348281A1 (pt)
DE (1) DE69918322T2 (pt)
DK (1) DK1124556T3 (pt)
ES (1) ES2224751T3 (pt)
GB (1) GB2367748A (pt)
HK (2) HK1040908B (pt)
IL (2) IL142803A0 (pt)
NZ (1) NZ511744A (pt)
PT (1) PT1124556E (pt)
WO (1) WO2000024400A1 (pt)
ZA (1) ZA200103376B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
JP2006514084A (ja) * 2002-12-03 2006-04-27 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３−ヒドロキシ−４−メトキシフェニル）−４−メチル−５−エチル−７，８−ジメトキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
MXPA05005895A (es) 2002-12-03 2006-02-08 Vela Pharmaceuticals Inc Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
JP2007513171A (ja) * 2003-12-03 2007-05-24 ヴェラ ファーマスーティカルズ インコーポレイテッド ２，３−ベンゾジアゼピン低投与量による上皮の炎症性疾患の治療
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
DK1124556T3 (da) 2004-10-11
JP2003522112A (ja) 2003-07-22
ATE269705T1 (de) 2004-07-15
GB0111739D0 (en) 2001-07-04
EP1124556A1 (en) 2001-08-22
NZ511744A (en) 2004-04-30
WO2000024400A1 (en) 2000-05-04
GB2367748A (en) 2002-04-17
GB2367748A8 (en) 2002-12-19
EP1124556B1 (en) 2004-06-23
HK1040908A1 (en) 2002-06-28
AU1451900A (en) 2000-05-15
ES2224751T3 (es) 2005-03-01
IL142803A (en) 2006-10-05
CA2348281A1 (en) 2000-05-04
DE69918322D1 (de) 2004-07-29
HK1040908B (zh) 2005-04-22
IL142803A0 (en) 2002-03-10
DE69918322T2 (de) 2005-09-15
ZA200103376B (en) 2003-09-09
HK1046500A1 (zh) 2003-01-17
JP2007211028A (ja) 2007-08-23
PT1124556E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DK2145627T3 (da) Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.
PT695758E (pt) Amidas e esteres de pentapeptidos inibidores de cancro humano
BG105112A (en) Agents with antidepressive effect
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
BR9914899A (pt) Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
DK1098649T3 (da) Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK0785948T3 (da) Analoger af keratinocyt vækstfaktor
LU91235I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (KEPIVANCE)
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
DK1161521T3 (da) Transplantation af hæmatopoietiske celler
BR9712100A (pt) Intermediários e processo para preparar olanzapina.
TR199900505T2 (pt)
ATE238054T1 (de) Pflaster zur transdermalen anwendung von pergolid
DK0928183T3 (da) Anvendelse af 1-hydroxy-2-pyridoner til behandling af seborrhoisk dermatitis
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DK0813870T3 (da) Anvendelse af darifenacin til at forstærke kognitive funktioner
DK0458590T3 (da) Behandling af okulær hypertension med en synergistisk konbination
BR9602295A (pt) Composição combinação estabilizada uso e processo para estabilização de CPVC
BR9704653A (pt) Processo para aumentar o tempo de vida útil de componentes dentários
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
BR9500886A (pt) Composições com efeito regulador de crescimento e método para o tratamento de culturas
DK0804199T3 (da) Anvendelse af penciclovir til behandling af postherpetisk neuralgi
DK0923534T3 (da) Fremgangsmåde til fremstilling af racemiske phenethylaminer

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.